Q2 EPS Estimates for Bausch + Lomb Lifted by HC Wainwright

Bausch + Lomb Corporation (NYSE:BLCO) – Equities researchers at HC Wainwright boosted their Q2 2026 EPS estimates for shares of Bausch + Lomb in a report issued on Monday, May 4th. HC Wainwright analyst Y. Chen now expects that the company will earn $0.21 per share for the quarter, up from their prior estimate of $0.18. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Bausch + Lomb’s current full-year earnings is $0.79 per share. HC Wainwright also issued estimates for Bausch + Lomb’s Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.34 EPS, Q2 2027 earnings at $0.22 EPS, Q3 2027 earnings at $0.23 EPS and Q4 2027 earnings at $0.41 EPS.

A number of other research analysts have also issued reports on the stock. The Goldman Sachs Group restated a “neutral” rating and set a $19.00 price target on shares of Bausch + Lomb in a research note on Friday, January 9th. Royal Bank Of Canada upped their price target on shares of Bausch + Lomb from $19.00 to $21.00 and gave the company an “outperform” rating in a research note on Tuesday, January 27th. Citigroup upped their price target on shares of Bausch + Lomb from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Evercore set a $18.00 price target on shares of Bausch + Lomb and gave the company an “in-line” rating in a research note on Monday, January 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Bausch + Lomb in a research note on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Bausch + Lomb currently has an average rating of “Hold” and an average target price of $18.08.

Bausch + Lomb Trading Down 0.0%

Shares of Bausch + Lomb stock opened at $16.31 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 0.99 and a debt-to-equity ratio of 0.78. Bausch + Lomb has a 12-month low of $10.83 and a 12-month high of $18.92. The firm has a market capitalization of $5.81 billion, a price-to-earnings ratio of -26.30, a PEG ratio of 0.52 and a beta of 0.59. The firm’s 50 day simple moving average is $16.65 and its two-hundred day simple moving average is $16.53.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Bausch + Lomb had a negative net margin of 4.21% and a positive return on equity of 3.60%. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the prior year, the business posted ($0.07) EPS. Bausch + Lomb’s revenue for the quarter was up 9.4% compared to the same quarter last year.

Institutional Trading of Bausch + Lomb

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its position in Bausch + Lomb by 104.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock valued at $38,000 after buying an additional 1,136 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in Bausch + Lomb by 729.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after buying an additional 2,042 shares during the period. Wells Fargo & Company MN grew its position in Bausch + Lomb by 31.2% during the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after buying an additional 1,403 shares during the period. Jones Financial Companies Lllp grew its position in Bausch + Lomb by 55.3% during the third quarter. Jones Financial Companies Lllp now owns 9,112 shares of the company’s stock valued at $132,000 after buying an additional 3,246 shares during the period. Finally, Invesco Ltd. acquired a new stake in Bausch + Lomb during the fourth quarter valued at $178,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Insider Activity at Bausch + Lomb

In other news, EVP A Robert D. Bailey purchased 14,600 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were bought at an average price of $17.15 per share, for a total transaction of $250,390.00. Following the completion of the transaction, the executive vice president owned 231,890 shares in the company, valued at $3,976,913.50. This represents a 6.72% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Sam Eldessouky purchased 4,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were purchased at an average price of $17.13 per share, for a total transaction of $68,520.00. Following the transaction, the chief financial officer owned 403,130 shares of the company’s stock, valued at $6,905,616.90. This trade represents a 1.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 33,300 shares of company stock worth $570,868. 1.45% of the stock is owned by company insiders.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.